Gu Wei, Guo Wen, Ren Zhishuang, Zhang Yimeng, Han Meiqi, Zhao Qinfu, Gao Yikun, Mao Yuling, Wang Siling
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China.
School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China.
Bioact Mater. 2024 May 14;38:472-485. doi: 10.1016/j.bioactmat.2024.04.029. eCollection 2024 Aug.
Reactive oxygen species (ROS) generated from photosensitizers exhibit great potential for repolarizing immunosuppressive tumor-associated macrophages (TAMs) toward the anti-tumor M1 phenotype, representing a promising cancer immunotherapy strategy. Nevertheless, their effectiveness in eliminating solid tumors is generally limited by the instability and inadequate TAMs-specific targeting of photosensitizers. Here, a novel core-shell integrated nano platform is proposed to achieve a coordinated strategy of repolarizing TAMs for potentiating cancer immunotherapy. Colloidal mesoporous silica nanoparticles (CMSN) are fabricated to encapsulate photosensitizer-Indocyanine Green (ICG) to improve their stability. Then ginseng-derived exosome (GsE) was coated on the surface of ICG/CMSN for targeting TAMs, as well as repolarizing TAMs concurrently, named ICG/CMSN@GsE. As expected, with the synergism of ICG and GsE, ICG/CMSN@GsE exhibited better stability, mild generation of ROS, favorable specificity toward M2-like macrophages, enhancing drug retention in tumors and superior TAMs repolarization potency, then exerted a potent antitumor effect. , experiment results also confirm the synergistic suppression of tumor growth accompanied by the increased presence of anti-tumor M1-like macrophages and maximal tumor damage. Taken together, by integrating the superiorities of TAMs targeting specificity and synergistic TAMs repolarization effect into a single nanoplatform, ICG/CMSN@GsE can readily serve as a safe and high-performance nanoplatform for enhanced cancer immunotherapy.
由光敏剂产生的活性氧(ROS)在将免疫抑制性肿瘤相关巨噬细胞(TAM)重极化至抗肿瘤M1表型方面具有巨大潜力,这代表了一种很有前景的癌症免疫治疗策略。然而,它们在消除实体瘤方面的有效性通常受到光敏剂的不稳定性和对TAM特异性靶向不足的限制。在此,提出了一种新型的核壳一体化纳米平台,以实现重极化TAM以增强癌症免疫治疗的协同策略。制备了胶体介孔二氧化硅纳米颗粒(CMSN)以包裹光敏剂吲哚菁绿(ICG),以提高其稳定性。然后将人参来源的外泌体(GsE)包被在ICG/CMSN表面,用于靶向TAM,并同时使TAM重极化,命名为ICG/CMSN@GsE。正如预期的那样,在ICG和GsE的协同作用下,ICG/CMSN@GsE表现出更好的稳定性、温和的ROS生成、对M2样巨噬细胞的良好特异性、增强药物在肿瘤中的保留以及优异的TAM重极化能力,进而发挥强大的抗肿瘤作用。实验结果还证实了对肿瘤生长的协同抑制,同时伴随着抗肿瘤M1样巨噬细胞的增加和最大程度的肿瘤损伤。综上所述,通过将TAM靶向特异性和协同TAM重极化效应的优势整合到单个纳米平台中,ICG/CMSN@GsE可以很容易地作为一种安全且高性能的纳米平台用于增强癌症免疫治疗。